TY - JOUR T1 - Tubular Breast Cancer. A Retrospective study JF - Anticancer Research JO - Anticancer Res SP - 3647 LP - 3656 VL - 34 IS - 7 AU - PETER FRITZ AU - KLAUS BENDRAT AU - MAIKE SONNENBERG AU - CHRISTIAN TRAUTMANN AU - GERMAN OTT AU - ELSE HEIDEMANN AU - FRIEDHELM BRINKMANN AU - SIMONE FAISST AU - ANDREAS GERTEIS AU - HILTRUD BRAUCH AU - MATTHIAS SCHWAB AU - CHRISTOPH LINDNER AU - KAY FRIEDRICHS AU - MARK DOMINIK ALSCHER AU - JUERGEN DIPPON AU - AXEL NIENDORF Y1 - 2014/07/01 UR - http://ar.iiarjournals.org/content/34/7/3647.abstract N2 - Background: The well-characterized tubular-type of breast tumors is classified as low-risk breast cancer. Patients and Methods: We report on the results of a retrospective analysis on clinical and biological features of 248 tubular breast tumors including follow-up and treatment data from two German series of 21,065 breast cancer cases. The majority of tumors were stage I or stage II, ER- and PR-positive and c-erbB2-negative with a 5-year survival-rate of 96.3%. 51.3% of patients received hormonal treatment, 75.5% had post-operative radiotherapy and 11.8% were treated with a chemotherapeutical regimen. Conclusion: Our retrospective analysis showed no treatment benefit for either anti-hormonal or chemotherapeutical regimens. Post-operative radiotherapy, however, improved the survival rate of patients with tubular carcinoma (log-rank=5, p=0.025). Our data suggest that post-operative radiotherapy is an important treatment to prolong survival for patients suffering from tubular breast cancer. ER -